News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Inspire Pharmaceuticals, Inc. Announces Progress In Cystic Fibrosis Program
November 3, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today several updates in its development program for denufosol tetrasodium for the treatment of cystic fibrosis (CF).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Events
MORE ON THIS TOPIC
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
October 23, 2025
·
3 min read
·
Tristan Manalac
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
October 22, 2025
·
4 min read
·
Tristan Manalac
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
October 22, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff
October 22, 2025
·
2 min read
·
Tristan Manalac
